SCHEMBL2180224

SCHEMBL2180224

C[Si](C)(C)c1cccnc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.48
ALDH1A1 P00352 4/20 0.48
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 1/20 0.48
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CHRNB2 P17787 3/20 0.40
CHRNA4 P43681 3/20 0.40
APP P05067 1/20 0.38
GAA P10253 1/20 0.38
HCAR3 P49019 1/20 0.38
HCAR2 Q8TDS4 1/20 0.38
CFTR P13569 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29505165 1.00 CYP2A6 (0.48) CYP2A6ALDH1A1CYP1A2CYP3A4KDM4E
SCHEMBL21490690 0.91 CYP2A6 (0.41) CYP2A6ALDH1A1CYP1A2CYP3A4KDM4E
SCHEMBL10479554 0.80 CYP2A6 (0.44) CYP2A6ALDH1A1CYP1A2CYP3A4KDM4E
SCHEMBL10479669 0.80 CYP2A6 (0.44) CYP2A6ALDH1A1CYP1A2CYP3A4KDM4E
SCHEMBL9138633 0.78 ESR1 (0.50) CYP2A6ALDH1A1CYP1A2CYP3A4KDM4E
SCHEMBL10479743 0.78 ALDH1A1 (0.42) CYP2A6ALDH1A1CYP1A2CYP3A4KDM4E
SCHEMBL9137368 0.77 KIF11 (0.41) CYP2A6ALDH1A1CYP1A2CYP3A4KDM4E
SCHEMBL2012822 0.75 CHRNA7 (0.44) CYP2A6ALDH1A1CYP1A2CYP3A4CHRNB2
SCHEMBL7032434 0.75 CYP2A6 (0.39) CYP2A6ALDH1A1CYP1A2CYP3A4KDM4E
SCHEMBL30272173 0.75 CYP2A6 (0.39) CYP2A6ALDH1A1CYP1A2CYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174502-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION 2023-06-08 US disclosed
EP-3792270-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE Samsung Electronics Co., Ltd. (KR) 2021-03-17 EP disclosed
CN-109983022-A As the chromans of mGluR2 negativity allosteric modulators, heterochromatic full and dihydroisobenzofuran derivative, composition and application thereof 默沙东公司 2019-07-05 CN disclosed
US-9818551-B2 Additive for electrolytic composition, electrolytic composition using this additive, and dye-sensitized solar cell ADEKA CORPORATION (JP) 2017-11-14 US disclosed
US-9818551-B2 Additive for electrolytic composition, electrolytic composition using this additive, and dye-sensitized solar cell ADEKA CORPORATION (JP) 2017-11-14 US disclosed
US-9818551-B2 Additive for electrolytic composition, electrolytic composition using this additive, and dye-sensitized solar cell ADEKA CORPORATION (JP) 2017-11-14 US disclosed
EP-2618420-B1 ADDITIVE FOR USE IN DYE-SENSITIZED SOLAR CELL ADEKA CORP (JP) 2016-12-07 EP disclosed
CN-105968142-A Organometallic compound and organic light-emitting device including the same 三星电子株式会社 2016-09-28 CN disclosed
EP-2618420-A1 ADDITIVE FOR ELECTROLYTIC COMPOSITION, ELECTROLYTIC COMPOSITION USING THIS ADDITIVE, AND DYE-SENSITIZED SOLAR CELL Adeka Corporation (JP) 2013-07-24 EP disclosed
US-20130161555-A1 ADDITIVE FOR ELECTROLYTIC COMPOSITION, ELECTROLYTIC COMPOSITION USING THIS ADDITIVE, AND DYE-SENSITIZED SOLAR CELL ADEKA CORPORATION (JP) 2013-06-27 US disclosed
EP-2160385-A1 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES Novogen Research Pty. Ltd. (AU) 2010-03-10 EP disclosed
US-20090176781-A1 Acetylenic Heteroaryl Compounds ARIAD PHARMACEUTICALS, INC. 2009-07-09 US disclosed
WO-2009003229-A1 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES NOVOGEN RESEARCH PTY LTD (AU) 2009-01-08 WO disclosed
US-20030139600-A1 2-pyridylsilane, processes for producing and using the same SUMITOMO CHEMICAL CO., LTD. 2003-07-24 US disclosed
US-6548673-B1 Alkylation using transition metal complex catalyst; purified by acid/base extraction SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-04-15 US disclosed
US-6531602-B2 Desilylation of a 2-pyridylsilane to form an alcohol SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-03-11 US disclosed
US-20020165397-A1 2-Pyridylsilane, processes for producing and using the same SUMITOMO CHEMICAL CO., LTD. 2002-11-07 US disclosed
EP-1035125-A2 2-Pyridylsilane, processes for producing and using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2000-09-13 EP disclosed
US-4857521-A Trialkylsilyl pyridinium cephalosporin antibiotics SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1989-08-15 US disclosed
EP-0231124-A2 Cephalosporin derivatives, salts thereof, process for their manufacture, and pharmaceutical agents comprising them SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1987-08-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165397-A1 2-Pyridylsilane, processes for producing and using the same H1-0, RIOK2, H1-4 CYP2A6 1139/4885ALDH1A1 497/4885CYP1A2 363/4885
US-20090176781-A1 Acetylenic Heteroaryl Compounds NAT1, AADAC, ACACA CYP2A6 61/4885ALDH1A1 148/4885CYP1A2 32/4885
US-20030139600-A1 2-pyridylsilane, processes for producing and using the same H1-0, H1-4, H1-2 CYP2A6 1185/4885ALDH1A1 479/4885CYP1A2 390/4885
US-20230174502-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES PAX2, PAX3, HPRT1 CYP2A6 4628/4885ALDH1A1 4415/4885CYP1A2 4316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.